Tabinda Razzaq

Dr. Tabinda Razzaq

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Insights-Journal of Health and Rehabilitation
Verified
Journal Article
Open access
PDF file
ATAsma Taj
Asma Taj
TRTabinda Razzaq
Tabinda Razzaq
MAMuhammad Sohaib Azeem
Muhammad Sohaib Azeem
SBSudhair Abbas Bangash
Sudhair Abbas Bangash
TMTalha Mazhar
Talha Mazhar
NANazeer Ahmed
Nazeer Ahmed
BackgroundArtificial Intelligence (AI) in clinical decision support systems (CDSS) has become an essential tool in improving patient outcomes, enhancing diagnostic accuracy, and assisting in treatment planning. However, healthcare professionals’ perceptions and accessibility to AI-powered CDSS vary across different roles, impacting their effectiveness. Understanding how clinicians, physicians, and nurses interact with AI can provide valuable insights for improving AI integration in hospitals. ObjectiveTo evaluate the perception, accessibility, and practical use of AI-powered CDSS among clinicians, physicians, and nurses in a hospital setting, focusing on how these factors influence the overall adoption and effectiveness of AI. MethodsA cross-sectional survey was conducted in a hospital setting in Sheikhupura, Pakistan, over three months (Feb 2024 to Apr 2024). A total of 54 participants were divided into three groups: clinicians (n=18), physicians (n=18), and nurses (n=18). Data was collected using a structured questionnaire assessing perception (positive/negative), accessibility (easy/complex), and beneficiaries of AI (yes/no). Descriptive statistics, chi-square tests, and ANOVA were used for data analysis, performed using SPSS version 25. ResultsClinicians showed the highest positive perception of AI at 83.3% (15/18), compared to 77.8% (14/18) for physicians and 55.6% (10/18) for nurses. AI accessibility was reported as easy by 66.7% (12/18) of clinicians, 55.6% (10/18) of physicians, and 44.4% (8/18) of nurses. Beneficiaries of AI were 72.2% (13/18) of clinicians, 66.7% (12/18) of physicians, and 50% (9/18) of nurses. Statistically significant differences were observed among the groups (p < 0.05). ConclusionThe study demonstrated that while clinicians and physicians generally have a positive perception and easier access to AI, nurses experience more challenges in both areas. Targeted interventions, including training and support, are essential to improving AI accessibility and perception across all healthcare professional groups for optimal clinical decision-making.

7 October 2024 in Journal of Pharmaceutical Research International
Verified
Journal Article
Open access
PDF file
AAAbu Sufiyan Ali
Abu Sufiyan Ali
ASAhmad Hanan Shah
Ahmad Hanan Shah
ASAhmad Safiyan
Ahmad Safiyan
MIMalaika Ijaz
Malaika Ijaz
HBHammad Ali Bhatti
Hammad Ali Bhatti
MIMuhammad Zahid Iqbal
Muhammad Zahid Iqbal
Background: Vaccination has significantly reduced the global burden of infectious diseases, preventing millions of deaths annually. Despite the availability of effective vaccines, suboptimal vaccination coverage remains a challenge, limiting the full realization of vaccination benefits. With their expertise in medication management and patient education, pharmacists play a crucial role in public health, particularly in vaccination services. But, due to low involvement of pharmacist specially Community Pharmacist who is available to public more than the other health care professionals effect the success and coverage of target immunization. Objective: This study aimed to evaluate the attitude and perceived barriers among community pharmacists in providing immunization services at community pharmacies in Lahore, Pakistan. Methods: This cross-sectional observational study was conducted in a different community pharmacy in Lahore city. A validated questionnaire was used for this study with a Cronbach alpha value of 0.721. The students of pharm-D distributed the questionnaire to pharmacists in various community pharmacies. The study assessed attitudes and barriers using a Likert scale and examined the impact of demographics such as gender, education, and work experience on these variables. Statistical Package for Social Science (SPSS) ver. 25.0 was used to analyze the data. Post-hoc pairwise comparison of chi-squared test for different variables with attitude and perceived barriers in community pharmacists is done. Results: The results revealed that male pharmacists had a slightly more positive attitude toward vaccinations than females, although the difference was not statistically significant (p = 0.094). Pharmacists with PhDs demonstrated a higher enthusiasm for providing vaccination services, which was attributed to their advanced knowledge. Full-time pharmacists exhibited better attitudes than part-time pharmacists, although this difference was also not statistically significant (p = 0.161). A key finding was the positive influence of vaccine availability, particularly Hepatitis B, on pharmacists' attitudes, with a statistically significant p-value of 0.003. However, several barriers persist, including inadequate training, lack of public trust, and limited vaccine access. These barriers were consistent across genders, as both male and female pharmacists reported similar challenges (p = 0.928). Conclusion: In conclusion, community pharmacists in Lahore demonstrate positive attitudes toward providing vaccination services. However, addressing the barriers to vaccination administration is essential for optimizing the pharmacists’ involvement in vaccination programs. The study highlights the need for targeted education and policy interventions to address these barriers and enhance pharmacists' roles in vaccination services, ultimately improving public health outcomes in Pakistan.

15 November 2023 in Universal Journal of Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
SSSara Shahid
Sara Shahid
FAFahad Ahmed
Fahad Ahmed
AMAbid Mustafa
Abid Mustafa
ASAnosh Sana
Anosh Sana
RKRabeel Khan
Rabeel Khan
MSMuhammad Saqlain
Muhammad Saqlain
Introduction: Tuberculosis is an infectious disease with high rates of infection and mortality throughout the world, but its spread is greater in developing countries, and its control is difficult. It is known that the most common side reaction of drug treatment for tuberculosis is hepatotoxicity resulting from the drugs, which negatively affects adherence to treatment as a result of patients not continuing to use it. Objective:This study aimed to determine the extent of hepatotoxicity as a result of drug treatment for tuberculosis. Methods: The study is a cross-sectional study conducted on TB patients undergoing TB treatment in a general hospital in Islamabad, Pakistan. A data collection form was used to obtain demographic and treatment data. The hepatotoxicity of TB drug therapy was evaluated by performing liver function tests (LFTs).Study duration was of 4 months. Results: The study showed that out of 100 tuberculosis patients, 55 patients were hepatotoxic. Hepatotoxic population includes 26% males and 29% females including almost 10% children either male or female. The maximun hepatotoxicity was observed in the patients undergoing combination therapy. Around 3-5 % patients showed that the Serum-GlutamicPyruvic-Transaminase (SGPT) values more than 2 times of their normal values. While other 50% showed hepatotoxicity 1-2 times of their normal values. Most of the patients found were in the age group ranging from 35-60 years. The main drugs used in tuberculosis treatment were: Isoniazid, Rifampicin, Pyrazinamide, Ethambutal. Conclusion:The rate of hepatotoxicity in TB patients on anti-TB treatment was high. The current study concluded that the more we move towards a greater number of drugs in combination, the greater the extent and chance of hepatotoxicity. The combination of three anti-tuberculosis drugs (isoniazid, rifampicin, and pyrazinamide) resulted in maximum hepatotoxicity. Peer Review History: Received: 21 August 2023; Revised: 18 September; Accepted: 19 October, Available online: 15 November 2023 Academic Editor: Dr. Marwa A. A. Fayed, University of Sadat City, Egypt, maafayed@gmail.com Received file: Reviewer's Comments: Average Peer review marks at initial stage: 6.0/10 Average Peer review marks at publication stage: 7.0/10 Reviewers: Dr. Owanaro Peter, Nigeria, Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Niger Delta University, Wilberforce Island, Bayelsa State, Nigeria. owonaropeter@gmail.com Prof. Hassan A.H. Al-Shamahy, Sana'a University, Yemen, shmahe@yemen.net.ye Dr. Sheikh Abdul Khaliq, Department of Pharmacy Practice, Faculty of Pharmacy, Hamdard University, Karachi, Pakistan, drwadhsheikh1974@gmail.com

20 August 2024 in Journal of Pharmaceutical Research International
Verified
Journal Article
Open access
PDF file
TRTabinda Razzaq
Tabinda Razzaq
RHRaza Hanif
Raza Hanif
MPMuhammad Haris Pervaiz
Muhammad Haris Pervaiz
SRShehzada Muhammad Afaq Raza
Shehzada Muhammad Afaq Raza
SZSamar Zia
Samar Zia
MIMuhammad Zahid Iqbal
Muhammad Zahid Iqbal
Background: Globally, cardiovascular diseases (CVDs) continue to be the primary cause of morbidity and mortality. Conditions including dyslipidemia, ischemic heart disease (IHD), and stroke play a significant role in this regard. Community pharmacists are essential in promoting health, especially when controlling risk factors like dyslipidemia and hypertension. However, little is known about community pharmacists' involvement in these initiatives in Pakistan, especially in Lahore. Objective: This study aimed to determine how involved community pharmacists in Lahore are in CVD-related health promotion initiatives and to analyze how they manage hypertension and dyslipidemia. Methods: This study is cross-sectional research conducted from May to August 2024—a self-structured questionnaire validated by experts with a Cronbach's value of 0.7291 is utilized for this study. The sample size was 113, determined by the convenient sampling method. The questionnaire included demographics, participation in cardiovascular health promotion, hypertension care services, and dyslipidemia care services. SPSS version 26 was used for the statistical analysis Results: In a study of 113 community pharmacists in Lahore, 53.1% were from the age group of 26-35 years, and only 2% were over 45. The study assessed pharmacists' roles in cardiovascular health promotion and management of hypertension and dyslipidemia. Findings revealed that 61.1% of pharmacists consistently counsel patients on healthy lifestyles, while 43.4% regularly educate patients about potential adverse drug reactions. However, only 22.1% of pharmacies offered diagnostic tests for dyslipidemia. The study highlights pharmacists' critical yet varied involvement in cardiovascular disease prevention and management. Conclusion: In this study, improved behavior was seen by the pharmacists as most of them always provide services to promote health in CVD patients and management of hypertension and dyslipidemia.

27 June 2024 in Medical Science
Verified
Journal Article
Closed access
TRTabinda Razzaq
Tabinda Razzaq
FWFatima Wajid
Fatima Wajid
SRSumbal Rafique
Sumbal Rafique
MNMuneeba Naveed
Muneeba Naveed
SSShanza Saadat
Shanza Saadat
MAMuhammad Awais
Muhammad Awais

11 September 2024
Verified
Journal Article
Open access
PDF file
SKSaliha Khalid
Saliha Khalid
TRTabinda Razzaq
Tabinda Razzaq
AKAfriaz Khan
Afriaz Khan
SASadia Afzal
Sadia Afzal
SAShiv Ram Ashraf
Shiv Ram Ashraf
ASAbbas Shahid
Abbas Shahid
Breast cancer (BC) is still the most commonly occurring malignancy in women and it poses a formidable public health challenge worldwide. It comprises a group of molecularly heterogeneous diseases in patients with a family history and/or suggestive personnel, and a predisposing gene is identified in <30% of patients in this type of malignancy. About 25% of heritable cases are due to a mutation in one of the few identified rare, but highly penetrant genes (BRCA1, BRCA2, PTEN, TP53, CDH1, and STK11), which confer up to 80% lifetime risk of BC. Additionally, 2%–3% of BC cases are due to a mutation in moderate-penetrance gene (e.g. CHEK2, BRIP1, ATM, and PALB2), and each gene is associated with a twofold increase in risk. BCs can begin in different areas of the breast, such as the ducts, the lobules, or the tissue in between. Within the large group of diverse breast carcinomas, there are various denoted types of BC based on their invasiveness relative to the primary tumor sites. For treatment of BCs, personalized cancer vaccination strategy can be an effective approach to trigger a broad-based antitumor response that is both beneficial and relevant to individual cancer patients. However, mRNA provides a template for the synthesis of any given protein, its fragment and lends itself to a broad range of pharmaceutical uses, including cancer immunotherapy. With the ease of rapid, large scale manufacturing and production, mRNA is ideally poised not only for off-the shelf cancer vaccines but also for personalized neoantigen vaccination. This review provides a comprehensive survey of the genetics, molecular mutations, and state-of-the-art information on vaccine-based therapeutics for BC.